- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
Advanced Therapy Medicinal Products (ATMP): cell and gene therapies.
- Gene therapy
- Cell therapy
- CAR-T cells
Medical
Regarding the activity of the MEARY Center, the very essence of which being the implementation of new bioproduction technologies and clinical trials, some projects have been implemented:
- Concerning academic projects: 1 early phase trials related to the transplantation of CAR-T cells in hematology (Prof. Nicolas BOISSEL), 1 RHU project (EpCART), selected for funding in 2021, in the field of CAR-T cells (Curie Institute/MNEMO Therapeutics/MEARY Center).
- Concerning industrial partnerships, the MEARY Center is involved in a clinical trial promoted by SMART IMMUNE (Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT, cleared by the FDA in the United States).
In December 2016, the CIC-BT became, alongside the hematology departments of Saint-Louis (Prof. Nicolas Boissel) and Robert Debré (Prof. André Baruchel), the phramacy and the apheresis unit of Saint-Louis, the first center in Europe to inject CAR-T cell therapy. The CIC-BT is identified as the "Pharmaceutical HUB" for the management of CAR-T cells at AP-HP. After paediatrics and young adult adolescents hematology units, the hemato-oncology department appropriated this revolutionary approach, first in Saint-Louis, and then in Pitié-Salpêtrière, Henri Mondor and Saint-Antoine hospitals. Today, 150 to 200 patients a year are treated at AP-HP.
- Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W; UCART19 Group. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020 Dec 12;396(10266):1885-1894.
- Cuffel A, Allain V, Faivre L, Di Blasi R, Morin F, Vercellino L, Chevalier MF, Desnoyer A, de Jorna R, Madelaine I, Parquet N, Brignier AC, Thieblemont C, Larghero J, Caillat-Zucman S, Mebarki M. Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma. Blood Adv. 2022 Aug 9;6(15):4657-4660.
- Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022 Nov;9(11):e833-e843.
National
European
International
